To deal with the soaring cost of ingredients, Domino's will be reducing the number of chicken wings in its $7.99 carryout deal from ten to eight wings instead of raising the price.
Domino's CEO Ritch Allison cited "unprecedented" ingredient cost increases, which according to CNN Business are between 8 and 10 percent higher than last year.
The $7.99 deal currently includes either ten wings or a large three-topping pizza, but the lesser takeout-only deal will take effect in a couple of weeks.
With customers selecting either a pizza or wings for the deal, Domino’s figured it would be an easier option to reduce chicken wings than charging different prices for the varying deals.
As an additional cost-cutting measure, the $7.99 deal would only be available for online orders to track consumer data better and hire fewer employees for taking phone calls.
Plus, customers tend to order more when placing online.
Almost half of Domino's orders are now being made digital and likely to increase further.


Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
U.S. Stock Futures Edge Higher Ahead of Big Tech Earnings and Fed Decision
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Global PCB Prices Surge Amid Middle East Conflict and Supply Chain Disruptions
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Asian Markets Mixed as Fed Decision, Iran Tensions, and Inflation Data Weigh on Sentiment
BOJ Governor Kazuo Ueda Hints at Rate Hike as Inflation Pressures Build
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Gold Prices Drop Amid Iran War Concerns, Rising Oil Costs, and Hawkish Central Bank Signals
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
US Sanctions Target Iran’s Shadow Banking Network and Terror Financing
Iraq Reaffirms Commitment to OPEC as UAE Exits Amid Global Energy Tensions
Gold Prices Fall as Strong Dollar and Rising Oil Prices Pressure Markets
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
European Stocks Slip as U.S.-Iran Tensions and Earnings Season Weigh on Markets
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



